Anavex Life Sciences Corp. (AVXL.OB) Completes Scale-up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer's Disease Clinical Trials
9/21/2009 10:35:17 AM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Reports Sigma Receptor Review Published in Leading Journal
8/27/2009 9:05:16 AM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Announces New CEO, Dr. Herve de Kergrohen
6/16/2009 8:02:11 AM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith To Scientific Advisory Board
2/10/2009 2:51:23 PM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer's Disease Study
2/2/2009 1:22:45 PM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Release: Ground-Breaking Anti-Amnesic And Neuroprotective Effects Of Alzheimer’s Compound Anavex 1-41 Published In Journal Of Neuropsychopharmacology
12/17/2008 1:57:32 PM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Presents Potent Neuroprotective Effects Of Anavex 1-41 At Neuroscience 2008
12/4/2008 2:10:51 PM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
9/2/2008 11:36:52 AM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) Presents Neuroprotective Effects of ANAVEX 1-41
7/30/2008 2:37:45 PM
More...
|
Anavex Life Sciences Corp. (AVXL.OB) will Present New Findings at the International Conference On Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, Usa)
6/25/2008 12:22:29 PM
More...
|
|